Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients
e al., Archives of Microbiology & Immunology, doi: (meta analysis)
, Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19.., e al., Archives of Microbiology & Immunology, doi: (meta analysis)
Analysis of the Fiolet meta analysis and correction of bias evaluation, showing HCQ RR 0.45 [0.31-0.59], and HCQ+AZ RR 0.34 [0.06-0.61].Currently there are 36 HCQ early treatment studies and meta analysis shows:
| Outcome | Improvement |
|---|---|
| Mortality | 72% lower [57‑81%] |
| Ventilation | 67% lower [-710‑99%] |
| ICU admission | 28% lower [-17‑55%] |
| Hospitalization | 41% lower [28‑52%] |
Lounnas et al., 9 Feb 2021, peer-reviewed, 4 authors.
Abstract: Arch Microbiol Immunology 2021; 5 (1): 154-175
10.26502/ami.93650055
Original Article
Revisiting a Meta-analysis Shows that Hydroxychloroquine with
Azithromycin may be Efficient in Covid-19 patients
Valère Lounnas1, Alexis Lacout2*, Xavier Azalbert3, Christian Perronne4
1
EMBL Heidelberg alumni, Meyerhofstraße 1, 69117, Heidelberg, Germany
2
Centre de diagnostic ELSAN, Centre médico –chirurgical, Aurillac, France
3
Toulouse School of Economics, 1988 Econometrics, France
4
Service des Maladies Infectieuses et Tropicales, University of Versailles Saint Quentin – Paris Saclay,
University Hospital Raymond Poincaré, Garches, France
*Corresponding Author: Alexis Lacout, Centre de diagnostic ELSAN, Centre Médico–Chirurgical, 83
avenue Charles de Gaulle, 15000, Aurillac, France, Tel: +33 687273707, Fax: +33 471485348; E-mail:
lacout.alexis@orange.fr
Received: 22 January 2021; Accepted: 02 February 2021; Published: 09 February 2021
Citation: Valère Lounnas, Alexis Lacout, Xavier Azalbert, Christian Perronne. Revisiting a Meta-analysis
Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients. Archives of
Microbiology & Immunology 5 (2021): 154-175.
Abstract
regarding the toxicity of the association HCQ plus
Objective: To analyze the impact of study
AZI is made.
selection on the results of a recently published
of
Results: Meta-analyses performed on the 11
and
studies we deem critically unbiased show a
hydroxychloroquine plus azithromycin (AZI) in
mortality reduction of 55% for HCQ and 66% for
Covid-19 patients.
HCQ plus AZI.
Methods: 31 studies were reviewed looking for
For both treatments, our meta-analysis indicates a
critical
significant efficacy in reducing mortality in
meta-analysis
of
the
hydroxychloroquine
bias.
Combined
efficacy
(HCQ)
hazard
ratios
and
confidence intervals were calculated for both
hospitalized Covid-19 patients.
treatments using a fixed effects size model and a
random
effects
model.
Quantitative
Archives of Microbiology & Immunology
analysis
Vol. 5 No. 1 – March 2021
154
Arch Microbiol Immunology 2021; 5 (1): 154-175
10.26502/ami.93650055
Keywords: Covid-19; Meta-analysis; Critical
they rely blindly on their calculations to firmly
bias;
suggest that: (1) HCQ alone does not show efficacy
Clinical
studies;
Hydroxychloroquine;
against Covid-19; and (2) any patient treated by
Azithromycin
HCQ and AZI, at any stage of the disease, would
1.
develop a high risk of cardiac failure subsequent to
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.